September 17, 2007 — Nucletron recently announced the successful management buy-out from Delft Instruments, creating an independent company fully dedicated to radiation oncology.
Since its inception in 1974, Nucletron has operated several entities in the field of radiation oncology throughout the world. The consolidation of the various entities into one, focused company further establishes Nucletron in a leadership role in this rapidly changing field. Collaborative partnerships, pioneering research and development of advanced technological innovations will enable Nucletron to more effectively deliver cancer treatment solutions globally and set the company apart within the industry.
The previous company, under Delft Instruments, was created in 1994 by merging Nucletron, the global leader in brachytherapy solutions, with the Oldelft Simulix brand of radiation therapy simulation and imaging technology. Additionally, in 2003, Nucletron integrated the Helax and Theratronics treatment planning and management solutions, from MDS Nordion, into its portfolio to create Oncentra MasterPlan and Oncentra Information Management.
With more than 10 percent of its revenues invested in research and development, Nucletron continuously seeks improvement of its existing product range and creation of new treatment options that improve patients' quality of care through curative and palliative treatment. The company's continued efforts in R&D, both in-house and through partnerships with leading academic institutions, have resulted in a strong and unique IP base.
The supervisory board of Nucletron will be chaired by Rob Westerhof, who has held senior positions in Asia and in the USA for Philips Medical Systems and Philips Electronics.
For more information: www.nucletron.com
March 12, 2024 
